Summary:
This is a study that seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
Qualified Participants Must:
• Be between 55 and 85 years of age
•
Have a reliable study partner
•
Have memory loss
Qualified Participants May Receive:
May be compensated for their time and travel.